# Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

> **NCT02288312** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 18 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** BIA 2-093

## Key facts

- **NCT ID:** NCT02288312
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02288312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02288312, "Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02288312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*